1111394-77-4

Usage

Primary uses

It is mainly used to treat erectile dysfunction and pulmonary arterial hypertension.

Mechanism of action

Sildenafil works by inhibiting the enzyme phosphodiesterase-5 (PDE5), leading to the relaxation of smooth muscle cells and increased blood flow in the penis, which improves erectile function.

Physical appearance

2-(4-methylpiperazin-1-yl)-5-nitrophenol is a yellow, crystalline powder.

Melting point

The compound has a melting point of 189-190°C.

Solubility

It is sparingly soluble in water.

Classification

The compound is classified as a PDE5 inhibitor.

Potential applications

Sildenafil has shown potential in treating various cardiovascular, neurological, and metabolic disorders.

Side effects

The compound carries potential side effects such as headache, flushing, dyspepsia, and nasal congestion.

Upstream product

• 109-01-3 1-methyl-piperazine 
• 22510-08-3 2-fluoro-5-nitrophenol 

Relevant academic research and scientific papers

The synthesis and bioactivity of pyrrolo[2,3-d]pyrimidine derivatives as tyrosine kinase inhibitors for NSCLC cells with EGFR mutations

EGFR mutations are an ongoing challenge in the treatment of NSCLC, and demand continuous updating of EGFR TKI drug candidates. Pyrrolopyrimidines are one group of versatile scaffolds suitable for tailored drug development. However not many precedents of this type of pharmacophore have been investigated in the realm of third generation of covalent EGFR-TKIs. Herein, a series of pyrrolo[2,3-d]pyrimidine derivatives able to block mutant EGFR activity in a covalent manner were synthesized, through optimized Buchwald-Hartwig C–N cross coupling reactions. Their preliminary bioactivity and corresponding inhibitory mechanistic pathways were investigated at molecular and cellular levels. Several compounds exhibited increased biological activity and enhanced selectivity compared to the control compound. Notably, compound 12i selectively inhibits HCC827 cells harboring the EGFR activating mutation with up to 493-fold increased efficacy compared to in normal HBE cells. Augmented selectivity was also confirmed by kinase enzymatic assay, with the test compound selectively inhibiting the T790 M activating mutant EGFRs (IC50 values of 0.21 nM) with up to 104-fold potency compared to the wild-type EGFR (IC50 values of 22 nM). Theoretical simulations provide structural evidence of selective kinase inhibitory activity. Thus, this series of pyrrolo[2,3-d]pyrimidine derivatives could serve as a starting point for the development of new EGFR-TKIs.

Pyrrolo [2, 3-d] pyrimidine derivative targeting EGFR mutation as well as preparation method and application of pyrrolo [2, 3-d] pyrimidine derivative

The invention provides a pyrrolo [2, 3-d] pyrimidine derivative targeting EGFR mutation as well as a preparation method and application thereof, and belongs to the field of chemical medicines. The derivative is a compound shown as a formula I, or a salt t